peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical postpones Annual General Meeting

24 Mar 2016, 08:00
Regulatory information
Hansa Medical AB (publ) announces that it´s Annual General Meeting is scheduled to be held May 11, 2016.

The company has previously announced that its Annual General Meeting was to be held April 27, 2016. The board of directors has resolved that the general meeting be postponed to be held May 11, 2016. The reason for the postponement is that the nomination committee needs more time for discussion with the company’s large shareholders due to the changes in ownership, which occurred on March 8, 2016.

Files

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70 633 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical’s share (ticker: HMED) is listed on Nasdaq Stockholm.